| Biotechnology Industry | Healthcare Sector | Mr. Tiejiong Fan CEO | SSE Exchange | CNE1000059X8 ISIN |
| CN Country | - Employees | 29 May 2026 Last Dividend | - Last Split | - IPO Date |
Shanghai Serum Bio-Technology Co., Ltd. is a biotechnology company focused on the research, development, manufacturing, and distribution of antitoxin and antiserum products. Established in 1999, the company has positioned itself as a leading entity in the field within China, operating from its base in Shanghai. Its commitment to enhancing public health is evident through its dedicated efforts in producing vital immunoglobulin and serum products to combat various diseases and toxic exposures.
This product is developed for the prevention and treatment of tetanus. Utilizing equine antibodies, it provides passive immunity to individuals exposed to the bacteria causing tetanus, offering critical protection in both post-injury prophylaxis and therapeutic contexts.
Shanghai Serum Bio-Technology's anti-venin products are designed to neutralize the effects of venom from snakes and other venomous animals. These products are crucial in areas where snake bites or venomous exposures are common, providing a life-saving treatment for affected individuals.
The anti-rabies serum provided by the company is an essential medical intervention against rabies, a deadly virus transmitted through the bites of infected animals. This product is part of the post-exposure prophylaxis regimen, aiming to prevent the virus from causing rabies in individuals with suspected exposure.